RELMADA THERAPEUTICS, INC.
RLMD$526M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCORAL GABLES17 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
RLMD News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
REL-1017
Depressive Disorder, Major
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Non Muscle Invasive Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
REL-1017 | Phase 3 | Depressive Disorder, Major | - | - |
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply